Breaking News

LGM Pharma Commits an Additional $9M to its Texas and Colorado Facilities

Will increase commercial capacity, expand R&D capabilities, and support continued demand for U.S.-based drug product manufacturing.

Author Image

By: Charlie Sternberg

Associate Editor

LGM Pharma, a provider of tailored API sourcing, contract analytical testing, and CDMO services for the full drug product lifecycle, has entered the second phase of its CDMO growth strategy, committing an additional $9 million to its facilities in Rosenberg, Texas, and Colorado Springs, Colorado. This investment follows the company’s previously announced $6 million expansion in Rosenberg in 2025 and is designed to increase commercial capacity, expand R&D capabilities, and support continue...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters